Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs iShares Self-Driving EV and Tech — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while iShares Self-Driving EV and Tech trades at $37.18. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| AMLX | IDRV | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Sector/Thematic |
52-Week High | $24.19 | $45.48 |
52-Week Low | $7.82 | $34.49 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
IDRV trades at $37.24, down 0.35% on the day, with a bullish technical signal driven by moving averages. The stock is positioned near its pivot point of $37, with key resistance at $38 and support at $36. Recent news highlights strong global EV sales growth and China's ambitious 2030 fleet target, supporting the thematic focus of the fund.
The outlook for IDRV is supported by positive industry trends in electric vehicles, though the absence of key valuation and profitability ratios limits fundamental assessment. Risks include competitive pressures and regulatory changes, while analyst sentiment is mixed with a slight bullish bias. The stock's performance remains tied to broader EV market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
